Molecular Markers Identify Subtypes of Stage III Colon Cancer Associated With Patient Outcomes

Grady, 2008, Genomic and epigenetic instability in colorectal cancer pathogenesis, Gastroenterology, 135, 1079, 10.1053/j.gastro.2008.07.076 Jass, 2007, Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, Histopathology, 50, 113, 10.1111/j.1365-2559.2006.02549.x Sinicrope, 2012, Molecular pathways: microsatellite instability in colorectal cancer: prognostic, predictive, and therapeutic implications, Clin Cancer Res, 18, 1506, 10.1158/1078-0432.CCR-11-1469 Ogino, 2009, CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer, Gut, 58, 90, 10.1136/gut.2008.155473 Hinoue, 2009, Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling, PLoS One, 4, e8357, 10.1371/journal.pone.0008357 Domingo, 2005, BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes, Oncogene, 24, 3995, 10.1038/sj.onc.1208569 Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 Rajagopalan, 2002, Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status, Nature, 418, 934, 10.1038/418934a Ogino, 2009, KRAS mutation in stage III colon cancer and clinical outcome following intergroup trial CALGB 89803, Clin Cancer Res, 15, 7322, 10.1158/1078-0432.CCR-09-1570 Jass, 1998, Morphology of sporadic colorectal cancer with DNA replication errors, Gut, 42, 673, 10.1136/gut.42.5.673 Ribic, 2003, Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer, N Engl J Med, 349, 247, 10.1056/NEJMoa022289 Sinicrope, 2013, Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy, J Clin Oncol, 31, 3664, 10.1200/JCO.2013.48.9591 Sinicrope, 2011, DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy, J Natl Cancer Inst, 103, 863, 10.1093/jnci/djr153 Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 Phipps, 2012, BRAF mutation status and survival after colorectal cancer diagnosis according to patient and tumor characteristics, Cancer Epidemiol Biomarkers Prev, 21, 1792, 10.1158/1055-9965.EPI-12-0674 Phipps, 2013, KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers, Br J Cancer, 108, 1757, 10.1038/bjc.2013.118 Samowitz, 2000, Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study, Cancer Epidemiol Biomarkers Prev, 9, 1193 Samowitz, 2005, Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers, Cancer Res, 65, 6063, 10.1158/0008-5472.CAN-05-0404 Gavin, 2012, Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive value, Clin Cancer Res, 18, 6531, 10.1158/1078-0432.CCR-12-0605 Samadder, 2013, Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women, Gastroenterology, 145, 348, 10.1053/j.gastro.2013.05.001 Leggett, 2010, Role of the serrated pathway in colorectal cancer pathogenesis, Gastroenterology, 138, 2088, 10.1053/j.gastro.2009.12.066 Bond, 2012, Chromosomal instability in BRAF mutant, microsatellite stable colorectal cancers, PLoS One, 7, e47483, 10.1371/journal.pone.0047483 Phipps, 2015, Association between molecular subtypes of colorectal cancer and patient survival, Gastroenterology, 148, 77, 10.1053/j.gastro.2014.09.038 Greene, 2002, 200 Andre, 2004, Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer, N Engl J Med, 350, 2343, 10.1056/NEJMoa032709 Alberts, 2012, Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial, JAMA, 307, 1383, 10.1001/jama.2012.385 Domingo, 2004, BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing, J Med Genet, 41, 664, 10.1136/jmg.2004.020651 Angulo, 2010, A commercial real-time PCR kit provides greater sensitivity than direct sequencing to detect KRAS mutations: a morphology-based approach in colorectal carcinoma, J Mol Diagn, 12, 292, 10.2353/jmoldx.2010.090139 Grady, 2001, Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer, Cancer Res, 61, 900 Kaplan, 1958, Nonparametric estimation from incomplete observations, J Am Stat Assn, 53, 457, 10.1080/01621459.1958.10501452 Cox, 1972, Regression models and life-tables, J R Stat Soc, 34, 187 R Development Core Team: A Language and Environment for Statistical Computing. Vienna, Austria, R Foundation for Statistical Computing, 2011. Available at: http://www.R-project.org/. Accessed September, 2014. Boland, 2010, Microsatellite instability in colorectal cancer, Gastroenterology, 138, 2073, 10.1053/j.gastro.2009.12.064 Kim, 2008, Distinct CpG island methylation profiles and BRAF mutation status in serrated and adenomatous colorectal polyps, Intl J Cancer, 123, 2587, 10.1002/ijc.23840 Popat, 2005, Systematic review of microsatellite instability and colorectal cancer prognosis, J Clin Oncol, 23, 609, 10.1200/JCO.2005.01.086 Burnett-Hartman, 2013, Genomic aberrations occurring in subsets of serrated colorectal lesions but not conventional adenomas, Cancer Res, 73, 2863, 10.1158/0008-5472.CAN-12-3462 De Sousa, 2013, Poor-prognosis colon cancer is defined by a molecularly distinct subtype and develops from serrated precursor lesions, Nat Med, 19, 614, 10.1038/nm.3174 Carragher, 2010, V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a, EMBO Mol Med, 2, 458, 10.1002/emmm.201000099 Rad, 2013, A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention, Cancer Cell, 24, 15, 10.1016/j.ccr.2013.05.014 Andre, 2009, Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial, J Clin Oncol, 27, 3109, 10.1200/JCO.2008.20.6771 Yothers, 2011, Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses, J Clin Oncol, 29, 3768, 10.1200/JCO.2011.36.4539 Kuebler, 2007, Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07, J Clin Oncol, 25, 2198, 10.1200/JCO.2006.08.2974 Sargent, 2010, Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer, J Clin Oncol, 28, 3219, 10.1200/JCO.2009.27.1825 Kang, 2013, Somatic gene mutations in African Americans may predict worse outcomes in colorectal cancer, Cancer Biomark, 13, 359, 10.3233/CBM-130366 Sylvester, 2012, Molecular analysis of colorectal tumors within a diverse patient cohort at a single institution, Clin Cancer Res, 18, 350, 10.1158/1078-0432.CCR-11-1397 Andreyev, 2001, Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study, Br J Cancer, 85, 692, 10.1054/bjoc.2001.1964 De Roock, 2010, Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis, Lancet Oncol, 11, 753, 10.1016/S1470-2045(10)70130-3 Imamura, 2012, Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers, Clin Cancer Res, 18, 4753, 10.1158/1078-0432.CCR-11-3210 Farina-Sarasqueta, 2010, The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients, Ann Oncol, 21, 2396, 10.1093/annonc/mdq258 Ogino, 2012, Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803, Clin Cancer Res, 18, 890, 10.1158/1078-0432.CCR-11-2246 Prahallad, 2012, Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR, Nature, 483, 100, 10.1038/nature10868 Corcoran, 2012, EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib, Cancer Discov, 2, 227, 10.1158/2159-8290.CD-11-0341